F. Barry Bays - 11 Apr 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for F. Barry Bays
Issuer symbol
TMCI
Transactions as of
11 Apr 2023
Net transactions value
-$2,263,499
Form type
4
Filing time
13 Apr 2023, 21:00:08 UTC
Previous filing
30 Mar 2023
Next filing
28 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale $1,176,286 -44,764 -3.7% $26.28 1,160,021 11 Apr 2023 Direct F1, F2
transaction TMCI Common Stock Sale $137,108 -5,026 -0.43% $27.28 1,154,995 11 Apr 2023 Direct F1, F3
transaction TMCI Common Stock Sale $950,104 -36,370 -3.1% $26.12 1,118,625 12 Apr 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.0100 to $26.9700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.1500 to $27.5700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.8400 to $26.5050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.